Navigation Links
Metabolex Appoints Donald Hill as Chief Financial Officer
Date:4/14/2008

HAYWARD, Calif., April 14 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that Donald M. Hill has joined the company as chief financial officer. Mr. Hill brings extensive financial and strategic planning experience to Metabolex, including expertise in business development, treasury management and controllership of large operating divisions. Mr. Hill joins Metabolex following more than 20 years in finance and corporate development management roles at Merck & Co., Inc., most recently as Assistant Treasurer, Global Capital Markets.

"The appointment of Don expands the depth of our already strong management team," said President and Chief Executive Officer Harold Van Wart, Ph.D. "Don's experience as a leader in a well respected, financially sophisticated pharmaceutical company, his experience in business development, and his strong analytical skills and strategic financial vision will be critical for us as we expand our product pipeline and move our clinical product candidates towards commercialization. With the company's four clinical product candidates and active discovery and preclinical development programs, Don's skills in financial planning and strategic product development will be invaluable."

Mr. Hill is a Chartered Financial Analyst (CFA), and holds a B.A. from the University of California, Berkeley and a Masters degree from the Sloan School of Management at the Massachusetts Institute of Technology.

About Metabolex

Metabolex is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, with an emphasis on type 2 diabetes. Metabolex has drawn on its deep understanding of diabetes to create a large database of genes involved in diabetes and to build a rich pipeline of product candidates and drug discovery targets. The company has four clinical-stage compounds: MBX-102/JNJ 39659100, which has recently completed a Phase 2/3 trial; MBX-2044, which has completed a Phase 2a trial; MBX-8025, currently being studied in a Phase 2 trial in patients with dyslipidemia; and MBX-2982, which has just commenced a Phase 1 trial. Ortho-McNeil, Inc. has the exclusive right to develop and commercialize MBX-102/JNJ 39659100. For additional information about Metabolex and its development pipeline, visit http://www.metabolex.com.


'/>"/>
SOURCE Metabolex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Biopure Appoints New Independent Auditor
2. Indivumed Appoints Annette Kassen as Vice President Clinical Research
3. ADVENTRX Appoints Vice President of Manufacturing
4. Egenix, Inc. Appoints Dr. Daniel Petrylak Chairman of Scientific Advisory Board
5. NanoLogix Inc. Provides Financial Update, Appoints Bert Pharis as New Director
6. Observant LLC Appoints Two New Directors to the Senior Management Team
7. Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer
8. Light Sciences Oncology Appoints David P. Holveck to Its Board of Directors
9. IDM Pharma Appoints Gregory J. Tibbitts to Board of Directors
10. Caliper Life Sciences Appoints Peter F. McAree Senior Vice President and Chief Financial Officer
11. PAREXEL Appoints Leading Central Nervous System Experts to Its Global Clinical Pharmacology Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... The American Medical Informatics ... of the National Coordinator for Health IT (ONC) outlining a measurement approach to ... were available when and where it was needed. The organization of health informatics ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... and traumatic injuries, will be accelerated by research at Worcester Polytechnic Institute (WPI) ... of wound healing and tissue regeneration. , The novel method, developed by WPI ...
(Date:5/23/2016)... ... May 23, 2016 , ... PrecisionAg® Media has released ... and Beyond. The paper outlines the key trends that are creating both opportunities ... witnessed a lot of highs and lows as the precision agriculture market has ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... on molecular nanotechnology, announced the winners for the 2015 Foresight Institute Feynman Prizes. ... are given in two categories, one for experiment and the other for theory ...
Breaking Biology Technology:
(Date:3/22/2016)... and SANDY, Utah , March ... operates the highest sample volume laboratory in ... and UNIConnect, leaders in clinical sequencing informatics and molecular ... of a project to establish the informatics infrastructure for ... NSO has been contracted by the Ontario Ministry ...
(Date:3/15/2016)... March 15, 2016 Yissum Research Development ... technology-transfer company of the Hebrew University, announced today the ... sensing technology of various human biological indicators. Neteera Technologies ... million from private investors. ... the detection of electromagnetic emissions from sweat ducts, enables ...
(Date:3/10/2016)... , March 10, 2016 ... market research report "Identity and Access Management Market by ... Compliance, and Governance), by Organization Size, by Deployment, by ... published by MarketsandMarkets, The market is estimated to grow ... Billion by 2020, at a Compound Annual Growth Rate ...
Breaking Biology News(10 mins):